Literature DB >> 25302161

Proton beam therapy for locally advanced lung cancer: A review.

Steven E Schild1, William G Rule1, Jonathan B Ashman1, Sujay A Vora1, Sameer Keole1, Aman Anand1, Wei Liu1, Martin Bues1.   

Abstract

Protons interact with human tissue differently than do photons and these differences can be exploited in an attempt to improve the care of lung cancer patients. This review examines proton beam therapy (PBT) as a component of a combined modality program for locally advanced lung cancers. It was specifically written for the non-radiation oncologist who desires greater understanding of this newer treatment modality. This review describes and compares photon (X-ray) radiotherapy (XRT) to PBT. The physical differences of these beams are described and the clinical literature is reviewed. Protons can be used to create treatment plans delivering significantly lower doses of radiation to the adjacent organs at risk (lungs, esophagus, and bone marrow) than photons. Clinically, PBT combined with chemotherapy has resulted in low rates of toxicity compared to XRT. Early results suggest a possible improvement in survival. The clinical results of proton therapy in lung cancer patients reveal relatively low rates of toxicity and possible survival benefits. One randomized study is being performed and another is planned to clarify the clinical differences in patient outcome for PBT compared to XRT. Along with the development of better systemic therapy, newer forms of radiotherapy such as PBT should positively impact the care of lung cancer patients. This review provides the reader with the current status of this new technology in treating locally advanced lung cancer.

Entities:  

Keywords:  3-D radiotherapy; Intensity modulated photon radiotherapy; Intensity modulated proton therapy; Intensity modulated radiotherapy; Lung cancer; Photons; Proton beam therapy; Protons; X-rays

Year:  2014        PMID: 25302161      PMCID: PMC4129522          DOI: 10.5306/wjco.v5.i4.568

Source DB:  PubMed          Journal:  World J Clin Oncol        ISSN: 2218-4333


  23 in total

1.  Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; M Tarayre; M J Lacombe-Terrier; A Laplanche; E Quoix; P Ruffie; M Martin; J Y Douillard
Journal:  J Natl Cancer Inst       Date:  1992-01-01       Impact factor: 13.506

2.  Proton radiation therapy offers reduced normal lung and bone marrow exposure for patients receiving dose-escalated radiation therapy for unresectable stage iii non-small-cell lung cancer: a dosimetric study.

Authors:  R Charles Nichols; Soon N Huh; Randal H Henderson; Nancy P Mendenhall; Stella Flampouri; Zuofeng Li; Harry J D'Agostino; J Davis Cury; Dat C Pham; Bradford S Hoppe
Journal:  Clin Lung Cancer       Date:  2011-04-27       Impact factor: 4.785

3.  Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer.

Authors:  Joe Y Chang; Xiaodong Zhang; Xiaochun Wang; Yixiu Kang; Beverly Riley; Stephen Bilton; Radhe Mohan; Ritsuko Komaki; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-05-06       Impact factor: 7.038

4.  Proton therapy with concurrent chemotherapy for non-small-cell lung cancer: technique and early results.

Authors:  Bradford S Hoppe; Stella Flampouri; Randal H Henderson; Dat Pham; Abubakr A Bajwa; Harry D'Agostino; Soon N Huh; Zuofeng Li; Nancy P Mendenhall; R Charles Nichols
Journal:  Clin Lung Cancer       Date:  2012-01-20       Impact factor: 4.785

5.  Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma.

Authors:  T Le Chevalier; R Arriagada; E Quoix; P Ruffie; M Martin; J Y Douillard; M Tarayre; M J Lacombe-Terrier; A Laplanche
Journal:  Lung Cancer       Date:  1994-03       Impact factor: 5.705

6.  Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT).

Authors:  Shulian Wang; Zhongxing Liao; Xiong Wei; Helen H Liu; Susan L Tucker; Chao-Su Hu; Rodhe Mohan; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-25       Impact factor: 7.038

7.  Intensity-modulated proton therapy reduces the dose to normal tissue compared with intensity-modulated radiation therapy or passive scattering proton therapy and enables individualized radical radiotherapy for extensive stage IIIB non-small-cell lung cancer: a virtual clinical study.

Authors:  Xiaodong Zhang; Yupeng Li; Xiaoning Pan; Li Xiaoqiang; Radhe Mohan; Ritsuko Komaki; James D Cox; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-08-05       Impact factor: 7.038

8.  Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer.

Authors:  K Furuse; M Fukuoka; M Kawahara; H Nishikawa; Y Takada; S Kudoh; N Katagami; Y Ariyoshi
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

9.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)

Authors:  M V Graham; J A Purdy; B Emami; W Harms; W Bosch; M A Lockett; C A Perez
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-09-01       Impact factor: 7.038

10.  Dose-volume thresholds and smoking status for the risk of treatment-related pneumonitis in inoperable non-small cell lung cancer treated with definitive radiotherapy.

Authors:  Hekun Jin; Susan L Tucker; Hui Helen Liu; Xiong Wei; Sue Sun Yom; Shulian Wang; Ritsuko Komaki; Yuhchyau Chen; Mary K Martel; Radhe Mohan; James D Cox; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2008-10-18       Impact factor: 6.280

View more
  11 in total

1.  The evolution of proton beam therapy: Current and future status.

Authors:  Xiufang Tian; Kun Liu; Yong Hou; Jian Cheng; Jiandong Zhang
Journal:  Mol Clin Oncol       Date:  2017-11-14

2.  Intensity-modulated proton therapy (IMPT) interplay effect evaluation of asymmetric breathing with simultaneous uncertainty considerations in patients with non-small cell lung cancer.

Authors:  Jie Shan; Yunze Yang; Steven E Schild; Thomas B Daniels; William W Wong; Mirek Fatyga; Martin Bues; Terence T Sio; Wei Liu
Journal:  Med Phys       Date:  2020-10-13       Impact factor: 4.071

Review 3.  Physics of Particle Beam and Hypofractionated Beam Delivery in NSCLC.

Authors:  Harald Paganetti; Clemens Grassberger; Gregory C Sharp
Journal:  Semin Radiat Oncol       Date:  2021-04       Impact factor: 5.421

4.  Assessment of Proton Beam Therapy Use Among Patients With Newly Diagnosed Cancer in the US, 2004-2018.

Authors:  Leticia M Nogueira; Ahmedin Jemal; K Robin Yabroff; Jason A Efstathiou
Journal:  JAMA Netw Open       Date:  2022-04-01

5.  Calotropin regulates the apoptosis of non‑small cell cancer by regulating the cytotoxic T‑lymphocyte associated antigen 4‑mediated TGF‑β/ERK signaling pathway.

Authors:  Lu Tian; Xiao-Hong Xie; Ze-Hao Zhu
Journal:  Mol Med Rep       Date:  2018-04-05       Impact factor: 2.952

6.  Combination of Proton Therapy and Radionuclide Therapy in Mice: Preclinical Pilot Study at the Paul Scherrer Institute.

Authors:  Cristina Müller; Maria De Prado Leal; Marco D Dominietto; Christoph A Umbricht; Sairos Safai; Rosalind L Perrin; Martina Egloff; Peter Bernhardt; Nicholas P van der Meulen; Damien C Weber; Roger Schibli; Antony J Lomax
Journal:  Pharmaceutics       Date:  2019-09-02       Impact factor: 6.321

Review 7.  Hadrontherapy Interactions in Molecular and Cellular Biology.

Authors:  Juliette Thariat; Samuel Valable; Carine Laurent; Siamak Haghdoost; Elodie A Pérès; Myriam Bernaudin; François Sichel; Paul Lesueur; Mathieu Césaire; Edwige Petit; Aurélie E Ferré; Yannick Saintigny; Sven Skog; Mihaela Tudor; Michael Gérard; Sebastien Thureau; Jean-Louis Habrand; Jacques Balosso; François Chevalier
Journal:  Int J Mol Sci       Date:  2019-12-24       Impact factor: 5.923

8.  Melittin suppresses growth and induces apoptosis of non-small-cell lung cancer cells via down-regulation of TGF-β-mediated ERK signal pathway.

Authors:  Renzhi Yu; Miao Wang; Minghuan Wang; Lei Han
Journal:  Braz J Med Biol Res       Date:  2020-12-18       Impact factor: 2.590

Review 9.  Proton beam radiotherapy for patients with early-stage and advanced lung cancer: a narrative review with contemporary clinical recommendations.

Authors:  Jennifer S Chiang; Nathan Y Yu; Thomas B Daniels; Wei Liu; Steven E Schild; Terence T Sio
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

10.  Technical Note: Multiple energy extraction techniques for synchrotron-based proton delivery systems may exacerbate motion interplay effects in lung cancer treatments.

Authors:  James E Younkin; Danairis Hernandez Morales; Jiajian Shen; Xiaoning Ding; Joshua B Stoker; Nathan Y Yu; Terence T Sio; Thomas B Daniels; Martin Bues; Mirek Fatyga; Steven E Schild; Wei Liu
Journal:  Med Phys       Date:  2021-07-29       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.